Oncology

Gastrointestinal Stromal Tumors

Expert Roundtables Podcast: Recent Advances in the Management of Gastrointestinal Stromal Tumors

expert roundtables by Ronald P. DeMatteo, MD, FACS; Richard F. Riedel, MD; Jonathan C. Trent, MD, PhD

Overview

<p>Recent surgical and medical advances have been made in managing gastrointestinal stromal tumors (GIST), including improved minimally invasive surgical techniques for smaller-sized primary localized and resectable tumors and tailored systemic treatment with TKIs based on mutational status and circulating tumor DNA for unresectable and advanced/metastatic disease. Join our experts as they provide updates on these advances in the management of GIST.</p>

References

ClinicalTrials.gov. A study of ziftomenib, an oral menin inhibitor, in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST). Updated November 5, 2025. Accessed November 7, 2025. https://clinicaltrials.gov/study/NCT06655246

ClinicalTrials.gov. (Peak) A phase 3 randomized trial of CGT9486 + sunitinib vs sunitinib in subjects with gastrointestinal stromal tumors. Updated May 9, 2025. Accessed November 7, 2025. https://clinicaltrials.gov/study/NCT05208047

Gómez-Peregrina D, Cicala CM, Serrano C. Monitoring advanced gastrointestinal stromal tumor with circulating tumor DNA. Curr Opin Oncol. 2024;36(4):282-290. doi:10.1097/CCO.0000000000001040

He C, Wang Z, Yu J, Mao S, Xiang X. Current drug resistance mechanisms and treatment options in gastrointestinal stromal tumors: summary and update. Curr Treat Options Oncol. 2024;25(11):1390-1405. doi:10.1007/s11864-024-01272-7

Larrain C, Pu T, Cox P, et al. INSIGHT: a phase III trial of ripretinib versus sunitinib in patients with advanced GIST with KIT exon 11 and exon 17/18 mutations who were previously treated with imatinib. Ann Surg Oncol. 2025;32(5):3065-3067. doi:10.1245/s10434-024-16853-x

Li J, Khajoueinejad N, Sarpel U. Surgical management of gastric gastrointestinal stromal tumors. Surg Clin North Am. 2025;105(1):109-124. doi:10.1016/j.suc.2024.06.009

Matheus GTFU, Ribeiro DM, Menegat ALRS, et al. Prognostic significance of circulating tumor DNA mutations in gastrointestinal stromal tumors: a systematic review and meta-analysis based on time-to-event data. J Gastrointest Cancer. 2025;56(1):153. doi:10.1007/s12029-025-01271-3

Schöffski P, Heinrich MC, Trent JC, et al. StrateGIST 1: a first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs). J Clin Oncol. 2024;42(suppl 16):11501. doi:10.1200/JCO.2024.42.16_suppl.11501

Xie F, Luo S, Liu D, et al. Genomic and transcriptomic landscape of human gastrointestinal stromal tumors. Nat Commun. 2024;15(1):9495. doi:10.1038/s41467-024-53821-1

Profile

Ronald P. DeMatteo, MD, FACS

John Rhea Barton Professor and Chair
Department of Surgery
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Profile

Richard F. Riedel, MD

Professor of Medicine With Tenure
Division of Medical Oncology
Duke University Medical Center
Associate Director of Clinical Research
Duke Sarcoma Center
Duke Cancer Institute
Durham, NC

Profile

Jonathan C. Trent, MD, PhD

Professor of Medicine
Associate Director for Clinical Research
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
Miami, FL